98%
921
2 minutes
20
The current experiment aimed to investigate the effects of TT powder on performance parameters and functional tests, as well as on morphological and histological changes in the liver, kidney and ileum in broiler chickens. Commercial broilers (total = 168 females) were used, equally divided into three dietary treatments (C = 0.0, T1 = 0.75, and T2 = 1.5 g/kg diet). The growth performance (1−35 days of age), absolute and relative weight, liver and kidney functional tests, intestinal morphology (14 and 35 days of age), and histomorphology of the ileum (35 days of age) were evaluated. At 35 days of age, histopathological changes in the ileum, liver, and kidney were also examined. The results showed that the growth performance and absolute and relative weights of the liver and kidney had no negative effects when dietary supplementation with TT powder was given at 0.75 g/kg diet (T1), whereas a decrease was observed at T2 (p < 0.05). Liver and kidney functional tests showed no significant effects in all feed treatments (14 days), while T1 showed lower (p < 0.05) ALT and AST levels (35 days). T1 exhibited higher weights, lengths, and weight-to-length ratios of the small intestine, and relative lengths of the duodenum (p < 0.05). Histomorphometric measurements of the ileum were higher (p < 0.05) in chickens fed the 0.75 g TT/kg diet, and except for in the goblet cell count and epithelial thickness, there were no differences between treatments (p > 0.05). In T1, hepatocytes were more normal but hepatic sinusoids were dilated, whereas in T2, lymphocytes had infiltrated around the central vein and lining endothelial cells had been lost. The kidney was improved in T1 and T2 compared with the control group. Ileal villi were shorter in T2, and some villi fused with enterocyte necrosis and inflammatory cells accumulated in the lumen. We concluded that TT powder (0.75 g/kg feed) has a safe effect and is healthy for broilers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367280 | PMC |
http://dx.doi.org/10.3390/ani12151930 | DOI Listing |
Clin Lab
September 2025
Background: Patients with epilepsy often require long-term antiepileptic medications, which can affect hematological parameters. Influenza (H1N1) infection is known to potentially cause thrombocytopenia. This case examines the clinical implications of a 29-year-old female patient with epilepsy who developed influenza and significant platelet reduction.
View Article and Find Full Text PDFTop Magn Reson Imaging
October 2025
BIOSPACE LAB, Nesles-la-Vallée, France.
Aims: Cardiac tumors are aggressive and asymptomatic in early stages, causing late diagnosis and locoregional metastasis. Currently, the standard of care uses gadolinium-based contrast agents for MRI, and the associated hypersensitivity reactions are a significant concern, such as gadolinium deposition disease. In addition, the proximity of cardiac lesions closer to vital structures complicates surgical interventions.
View Article and Find Full Text PDFTurkiye Parazitol Derg
September 2025
COMSATS University Islamabad (CUI) Faculty of Health Sciences, Department of Biosciences, Islamabad, Pakistan.
Objective: Present study aimed to determine the demographic, epidemiological and pathological features of human cystic echinococcosis (CE) cases using patients' hospital based clinical history from 2012-2023.
Methods: The current retrospective study was conducted from June-December and aimed to investigate the incidence of human CE in Pakistan. A total of 74 surgically confirmed patients' data was retrieved from the hospital records.
JCI Insight
September 2025
Alice and Y. T. Chen Center for Genetics and Genomics, Division of Medical Genetics, Department of Pediatrics.
Methylmalonic acidemia (MMA) is a severe metabolic disorder affecting multiple organs because of a distal block in branched-chain amino acid (BCAA) catabolism. Standard of care is limited to protein restriction and supportive care during metabolic decompensation. Severe cases require liver/kidney transplantation, and there is a clear need for better therapy.
View Article and Find Full Text PDFTher Deliv
September 2025
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), An Institute of National Importance, Government of India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Gandhinagar, India.
Background: Type 2 diabetes mellitus (T2DM) is the most devastating disease and it necessitates therapeutic intervention for its effective management. Human Glucagon-like peptide-1 (HuGLP-1) is the potential candidate in the treatment of T2DM; however, it limits its utilization owing to its solubility and stability issues.
Aims: The current investigation aims to develop HuGLP-1-loaded bilosomes as a novel strategy for managing T2DM.